Skip to main content
. Author manuscript; available in PMC: 2014 Mar 31.
Published in final edited form as: Biomaterials. 2013 Dec 9;35(6):1967–1976. doi: 10.1016/j.biomaterials.2013.10.075

Fig. 2.

Fig. 2

(A) The amount of IgG4.1 retained in curcumin or dexamethasone (dex) loaded nanovehicles (NVs; contains IgG4.1). *p < 0.05 (n = 3); 20 µg of IgG4.1/mg curcumin-NVs vs 10 µg of IgG4.1 g/mg curcumin-NVs. (B) Binding of NVs to 10 µg/ml fibrillar DutchAβ40. *p < 0.005 (n = 3); 14 mg of IgG4.1/mg curcumin-NVs and dexamethasone-NVs vs 7 mg of IgG4.1/mg curcumin-NVs. (C) Substantiation of IgG4.1 conjugation to the NVs by Western blot. (D) The percentage of free and bound 125I in the 125I-IgG4.1 conjugated nanovehicle formulation as shown by paper chromatography.